Fine-tuning the cardiac O-GlcNAcylation regulatory enzymes governs the functional and structural phenotype of the diabetic heart.
Darnel Prakoso, Shiang Y Lim, Jeffrey R Erickson, Rachel S Wallace, Jarmon G Lees, Mitchel Tate, Helen Kiriazis, Daniel G Donner, Darren C Henstridge, Jonathan R Davey, Hongwei Qian, Minh Deo, Laura J Parry, Amy J Davidoff, Paul Gregorevic, John C Chatham, Miles J De Blasio, Rebecca H Ritchie
Cardiovasc Res | Published : 2021
AIMS: The glucose-driven enzymatic modification of myocardial proteins by the sugar moiety, β-N-acetylglucosamine (O-GlcNAc), is increased in pre-clinical models of diabetes, implicating protein O-GlcNAc modification in diabetes-induced heart failure. Our aim was to specifically examine cardiac manipulation of the two regulatory enzymes of this process on the cardiac phenotype, in the presence and absence of diabetes, utilising cardiac-targeted recombinant-adeno-associated viral-vector-6 (rAAV6)-mediated gene delivery. METHODS AND RESULTS: In human myocardium, total protein O-GlcNAc modification was elevated in diabetic relative to non-diabetic patients, and correlated with left ventricular ..View full abstract
Awarded by Health Research Council of New Zealand Project
Awarded by NHMRC to R.H.R.
Awarded by Diabetes Australia
Awarded by National Health and Medical Research Council